Middleby Appoints Glenn Eisenberg to Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy LH?
Source: Newsfilter
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 258.050
Low
270.00
Averages
304.45
High
325.00
Current: 258.050
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Knoa Pharma Establishes New Board to Enhance Public Health Initiatives
- Company Formation Background: Knoa Pharma LLC begins operations independently on May 1, 2026, aiming to ensure safe access to critical medicines while addressing the opioid crisis and enhancing public health, marking a new chapter following Purdue Pharma's bankruptcy.
- Innovative Governance Structure: Knoa Pharma is 100% owned by the newly established non-profit Knoa Foundation, which has created two independent boards to ensure strong oversight and accountability in drug production and distribution, thereby enhancing public trust.
- Commitment to Public Health: Knoa Pharma will manufacture existing medicines, including opioid analgesics, safely and responsibly without promoting opioid products, operating under a strict injunction to minimize the risk of drug diversion and support the U.S. response to the opioid crisis.
- Leadership Team Composition: The new board comprises leaders with extensive experience in public health, drug policy, and corporate governance, ensuring the company meets critical patient needs while promoting sustainable and transparent operations that enhance social responsibility.
See More
Labcorp (LH) Q1 2026 Earnings Call Transcript
See More
Labcorp Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Labcorp reported Q1 revenue of $3.5 billion, a 6% increase year-over-year, with adjusted earnings per share rising 11%, indicating strong momentum in both Diagnostics and Central Laboratory businesses, enhancing market competitiveness.
- Strategic Collaboration Expansion: The company announced a nationwide strategic collaboration with the Children's Hospital of Philadelphia to provide advanced diagnostics for pediatric patients, while completing the acquisition of select assets from Crouse Health's Laboratory Alliance, further solidifying its market position.
- Strong Consumer Health Performance: The Consumer Health segment delivered double-digit growth, with the MyLabcorp mobile app set to launch in May, featuring an AI assistant to simplify appointment scheduling and payments, which is expected to enhance customer experience and market share.
- Optimistic Financial Outlook: The company raised the midpoint of its 2026 enterprise revenue and EPS guidance by approximately $30 million and $0.13, respectively, expecting enterprise revenue growth of 5% to 6.1%, reflecting confidence in future performance.
See More
Labcorp Q1 Earnings Exceed Expectations
- Earnings Beat: Labcorp reported a Q1 non-GAAP EPS of $4.25, beating expectations by $0.13, which underscores the company's strong profitability and boosts investor confidence.
- Revenue Growth: The company achieved revenue of $3.54 billion, a 5.7% year-over-year increase, exceeding expectations by $30 million, indicating its sustained competitive strength and business expansion capabilities.
- Guidance Raised: Labcorp raised its full-year enterprise revenue guidance to 5.0% to 6.1%, with the midpoint up 20 basis points, and adjusted EPS guidance of $17.70 to $18.35, surpassing the $17.79 consensus by 13 cents, reflecting confidence in future performance.
- Positive Stock Reaction: Following the earnings release, Labcorp's shares rose by 2.3%, demonstrating market recognition of its financial performance and outlook, potentially attracting more investor interest.
See More
Labcorp Reports Strong Q1 Results, Raises Adjusted EPS Guidance to $18.03
- Significant Revenue Growth: Labcorp achieved total revenue of $3.54 billion in Q1 2026, reflecting a 5.8% year-over-year increase, driven by robust growth in its Diagnostics and Central Laboratory segments, underscoring the company's leadership in complex testing needs.
- Adjusted EPS Guidance Raised: The company raised its 2026 adjusted EPS guidance to $18.03, an increase of $0.13 from previous estimates, reflecting sustained business momentum and effective execution of strategic priorities, thereby enhancing investor confidence.
- Disciplined Capital Allocation: In Q1 2026, Labcorp invested $202.2 million in acquisitions, repurchased $98.0 million in stock, and paid out $61.2 million in dividends, demonstrating the company's disciplined approach to capital allocation and commitment to shareholder returns.
- Technology Investment Drives Innovation: Labcorp's investments in advanced technologies, including robotics and AI, are improving customer experience and transforming operational methods, indicating the company's commitment to enhancing market competitiveness and meeting increasingly complex customer demands.
See More
Labcorp Q1 Earnings Announcement Scheduled
- Earnings Release Date: Labcorp Holdings (LH) is set to announce its Q1 earnings on April 30 before market open, with a consensus EPS estimate of $4.12, reflecting a 12% year-over-year increase, which could boost investor confidence and potentially drive stock price appreciation.
- Revenue Expectations: The anticipated revenue for Q1 is $3.51 billion, representing a 4.8% year-over-year growth, indicating the company's stable growth in the market, which may attract more investor interest in its future prospects.
- Historical Performance Review: Over the past two years, Labcorp has beaten EPS estimates 88% of the time and revenue estimates 63% of the time, and this strong performance record may enhance market expectations for its upcoming earnings report.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 6 upward revisions and 6 downward revisions, while revenue estimates have experienced 5 upward and 4 downward revisions, indicating a divergence in market sentiment regarding Labcorp's future performance, which could influence investor decisions.
See More
Knoa Pharma Establishes New Board to Enhance Public Health Initiatives
- Company Formation Background: Knoa Pharma LLC begins operations independently on May 1, 2026, aiming to ensure safe access to critical medicines while addressing the opioid crisis and enhancing public health, marking a new chapter following Purdue Pharma's bankruptcy.
- Innovative Governance Structure: Knoa Pharma is 100% owned by the newly established non-profit Knoa Foundation, which has created two independent boards to ensure strong oversight and accountability in drug production and distribution, thereby enhancing public trust.
- Commitment to Public Health: Knoa Pharma will manufacture existing medicines, including opioid analgesics, safely and responsibly without promoting opioid products, operating under a strict injunction to minimize the risk of drug diversion and support the U.S. response to the opioid crisis.
- Leadership Team Composition: The new board comprises leaders with extensive experience in public health, drug policy, and corporate governance, ensuring the company meets critical patient needs while promoting sustainable and transparent operations that enhance social responsibility.
See More
Labcorp (LH) Q1 2026 Earnings Call Transcript
See More
Labcorp Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Labcorp reported Q1 revenue of $3.5 billion, a 6% increase year-over-year, with adjusted earnings per share rising 11%, indicating strong momentum in both Diagnostics and Central Laboratory businesses, enhancing market competitiveness.
- Strategic Collaboration Expansion: The company announced a nationwide strategic collaboration with the Children's Hospital of Philadelphia to provide advanced diagnostics for pediatric patients, while completing the acquisition of select assets from Crouse Health's Laboratory Alliance, further solidifying its market position.
- Strong Consumer Health Performance: The Consumer Health segment delivered double-digit growth, with the MyLabcorp mobile app set to launch in May, featuring an AI assistant to simplify appointment scheduling and payments, which is expected to enhance customer experience and market share.
- Optimistic Financial Outlook: The company raised the midpoint of its 2026 enterprise revenue and EPS guidance by approximately $30 million and $0.13, respectively, expecting enterprise revenue growth of 5% to 6.1%, reflecting confidence in future performance.
See More
Labcorp Q1 Earnings Exceed Expectations
- Earnings Beat: Labcorp reported a Q1 non-GAAP EPS of $4.25, beating expectations by $0.13, which underscores the company's strong profitability and boosts investor confidence.
- Revenue Growth: The company achieved revenue of $3.54 billion, a 5.7% year-over-year increase, exceeding expectations by $30 million, indicating its sustained competitive strength and business expansion capabilities.
- Guidance Raised: Labcorp raised its full-year enterprise revenue guidance to 5.0% to 6.1%, with the midpoint up 20 basis points, and adjusted EPS guidance of $17.70 to $18.35, surpassing the $17.79 consensus by 13 cents, reflecting confidence in future performance.
- Positive Stock Reaction: Following the earnings release, Labcorp's shares rose by 2.3%, demonstrating market recognition of its financial performance and outlook, potentially attracting more investor interest.
See More
Labcorp Reports Strong Q1 Results, Raises Adjusted EPS Guidance to $18.03
- Significant Revenue Growth: Labcorp achieved total revenue of $3.54 billion in Q1 2026, reflecting a 5.8% year-over-year increase, driven by robust growth in its Diagnostics and Central Laboratory segments, underscoring the company's leadership in complex testing needs.
- Adjusted EPS Guidance Raised: The company raised its 2026 adjusted EPS guidance to $18.03, an increase of $0.13 from previous estimates, reflecting sustained business momentum and effective execution of strategic priorities, thereby enhancing investor confidence.
- Disciplined Capital Allocation: In Q1 2026, Labcorp invested $202.2 million in acquisitions, repurchased $98.0 million in stock, and paid out $61.2 million in dividends, demonstrating the company's disciplined approach to capital allocation and commitment to shareholder returns.
- Technology Investment Drives Innovation: Labcorp's investments in advanced technologies, including robotics and AI, are improving customer experience and transforming operational methods, indicating the company's commitment to enhancing market competitiveness and meeting increasingly complex customer demands.
See More
Labcorp Q1 Earnings Announcement Scheduled
- Earnings Release Date: Labcorp Holdings (LH) is set to announce its Q1 earnings on April 30 before market open, with a consensus EPS estimate of $4.12, reflecting a 12% year-over-year increase, which could boost investor confidence and potentially drive stock price appreciation.
- Revenue Expectations: The anticipated revenue for Q1 is $3.51 billion, representing a 4.8% year-over-year growth, indicating the company's stable growth in the market, which may attract more investor interest in its future prospects.
- Historical Performance Review: Over the past two years, Labcorp has beaten EPS estimates 88% of the time and revenue estimates 63% of the time, and this strong performance record may enhance market expectations for its upcoming earnings report.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 6 upward revisions and 6 downward revisions, while revenue estimates have experienced 5 upward and 4 downward revisions, indicating a divergence in market sentiment regarding Labcorp's future performance, which could influence investor decisions.
See More
